SPRY
ARS Pharmaceuticals, Inc. NASDAQ Listed Dec 4, 2020$9.65
-2.53%
vs $9.90
Mkt Cap $951.2M
52w Low $6.73
25.1% of range
52w High $18.35
50d MA $8.56
200d MA $9.38
P/E (TTM)
-5.5x
EV/EBITDA
—
P/B
8.3x
Debt/Equity
0.8x
ROE
-149.9%
P/FCF
-5.6x
RSI (14)
57.30
ATR (14)
$0.57
Beta
0.93
50d MA
$8.56
200d MA
$9.38
Avg Volume
1.6M
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
3525 Del Mar Heights Road · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | BMO | -0.53 | -0.61 | -15.1% | 7.94 | -6.8% | -6.4% | -1.7% | -1.8% | +8.8% | +5.5% | — |
| Mar 9, 2026 | BMO | -0.42 | -0.42 | +0.0% | 9.05 | +0.6% | -2.1% | -5.4% | -1.7% | +1.8% | +3.7% | — |
| Nov 10, 2025 | BMO | -0.45 | -0.52 | -15.6% | 8.88 | -1.7% | -1.2% | +2.1% | -6.0% | -2.4% | -10.8% | — |
| Aug 13, 2025 | BMO | -0.41 | -0.46 | -12.2% | 15.82 | -0.9% | -8.5% | +0.4% | -3.4% | -1.7% | +5.9% | — |
| May 14, 2025 | BMO | -0.35 | -0.35 | +0.0% | 12.10 | +0.5% | +0.8% | +11.5% | +4.9% | +0.5% | -0.8% | — |
| Mar 20, 2025 | BMO | -0.04 | 0.52 | +1400.0% | 14.31 | -0.4% | -13.6% | +4.3% | +2.0% | -4.2% | +0.2% | — |
| Nov 13, 2024 | BMO | -0.18 | -0.20 | -11.1% | 14.08 | +3.1% | +0.2% | -0.7% | -1.6% | +0.1% | -1.7% | — |
| Aug 6, 2024 | BMO | -0.12 | -0.13 | -8.3% | 9.78 | -1.0% | -2.1% | +3.3% | +10.0% | -0.3% | +20.4% | — |
| May 9, 2024 | BMO | -0.11 | -0.11 | +0.0% | 8.80 | +1.5% | -0.7% | +1.7% | +1.0% | -1.1% | +2.5% | — |
| Mar 21, 2024 | BMO | -0.14 | -0.07 | +50.0% | 9.00 | +0.0% | -3.9% | +5.5% | +9.5% | -0.4% | +2.6% | — |
| Nov 9, 2023 | BMO | -0.18 | -0.16 | +11.1% | 3.43 | +4.4% | +8.7% | +7.2% | +5.8% | +7.1% | -0.4% | — |
| Aug 10, 2023 | BMO | -0.17 | -0.18 | -5.9% | 6.85 | -0.6% | -0.3% | +1.3% | +1.7% | -2.6% | -1.9% | — |
| May 15, 2023 | AMC | -0.17 | -0.16 | +5.9% | 7.81 | -1.3% | +4.6% | +1.5% | -6.5% | +10.6% | +6.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 14 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $11.26 | $11.91 | +5.8% | +0.9% | +5.7% | +1.4% | +3.2% | +7.2% |
| Jan 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $11.24 | $11.40 | +1.4% | +0.2% | +0.9% | +5.7% | +1.4% | +3.2% |
| Oct 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.66 | $13.70 | +0.3% | +1.6% | -1.2% | +1.5% | +4.4% | +3.0% |
| Sep 20 | Leerink Partners | Maintains | Outperform → Outperform | — | $14.86 | $14.97 | +0.7% | -0.6% | -4.6% | -2.9% | +2.7% | +3.3% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.30 | $13.43 | +1.0% | -2.6% | +0.8% | +7.7% | +5.8% | -0.6% |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.36 | $11.49 | +1.1% | +3.1% | -1.7% | +4.3% | +5.2% | +5.3% |
| Aug 13 | Raymond James | Upgrade | Outperform → Strong Buy | — | $10.85 | $12.00 | +10.6% | +20.4% | -0.5% | +4.2% | -1.6% | +6.8% |
| Mar 11 | Wedbush | Maintains | Outperform → Outperform | — | $8.69 | $8.59 | -1.2% | -4.6% | +2.1% | +6.4% | +0.0% | +1.8% |
| Mar 5 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $8.65 | $9.32 | +7.7% | +2.7% | +0.5% | +0.3% | -2.9% | -4.6% |
| Nov 13 | Wedbush | Maintains | Outperform → Outperform | — | $3.73 | $3.90 | +4.6% | +7.2% | +5.8% | +7.1% | -0.4% | +4.4% |
| Sep 21 | Wedbush | Maintains | Outperform → Outperform | — | $2.92 | $2.80 | -4.1% | +25.7% | +7.9% | -9.1% | +4.2% | -2.9% |
| Sep 20 | William Blair | Downgrade | Outperform → Market Perform | — | $6.61 | $2.79 | -57.8% | -55.8% | +25.7% | +7.9% | -9.1% | +4.2% |
| Aug 14 | Wedbush | Maintains | Outperform → Outperform | — | $6.83 | $6.77 | -0.9% | +1.3% | +1.7% | -2.6% | -1.9% | -0.7% |
| Jun 21 | Wedbush | Maintains | Outperform → Outperform | — | $6.26 | $6.24 | -0.3% | +1.4% | +1.1% | -2.2% | +0.8% | +2.7% |
| May 18 | Wedbush | Maintains | Outperform → Outperform | — | $8.29 | $8.29 | +0.0% | -6.5% | +10.6% | +6.1% | -7.6% | +1.3% |
| May 12 | Wedbush | Maintains | Outperform → Outperform | — | $4.52 | $6.96 | +54.0% | +77.9% | -2.9% | +4.6% | +1.5% | -6.5% |
| Apr 3 | Goldman Sachs | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Mar 31 | Stifel | Downgrade | Buy → Hold | — | $3.52 | $3.48 | -1.1% | -0.3% | -8.5% | +0.9% | +3.7% | -2.4% |
| Mar 31 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $3.52 | $3.48 | -1.1% | -0.3% | -8.5% | +0.9% | +3.7% | -2.4% |
| Mar 31 | JonesTrading | Downgrade | Buy → Hold | — | $3.52 | $3.48 | -1.1% | -0.3% | -8.5% | +0.9% | +3.7% | -2.4% |
| Mar 31 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $3.52 | $3.48 | -1.1% | -0.3% | -8.5% | +0.9% | +3.7% | -2.4% |
| Nov 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $8.23 | $8.42 | +2.3% | +2.3% | +0.4% | +2.8% | -2.0% | -0.1% |
| Aug 15 | SVB Leerink | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| May 16 | SVB Leerink | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Apr 5 | SVB Leerink | Maintains | Outperform → Outperform | — | $44.28 | $44.79 | +1.2% | -5.5% | -4.9% | -2.9% | +3.8% | -5.1% |
| Mar 29 | Stifel | Maintains | Buy → Buy | — | $47.31 | $47.00 | -0.7% | -9.1% | -5.7% | +7.5% | +1.5% | -5.5% |
No insider trades available.
8-K · 2.02
!! High
ARS Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
May 15
8-K
ARS Pharmaceuticals, Inc. -- 8-K Filing
May 13
8-K · 7.01
! Medium
ARS Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
ARS Pharmaceuticals updated its investor presentation on March 9, 2026, potentially signaling new strategic messaging or financial updates for stakeholders to review.
Mar 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Deerfield Management Company, L.p. | 7,503,812 | $60M | — | Mar 2026 |
| 2 | Millennium Management | 5,982,919 | $48M | Added | Mar 2026 |
| 3 | Tyro Capital Management Llc | 3,989,704 | $46M | New | Dec 2025 |
| 4 | Aberdeen Group Plc | 4,113,617 | $33M | Added | Mar 2026 |
| 5 | Franklin Resources Inc | 3,278,549 | $26M | Added | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 2,542,504 | $20M | New | Mar 2026 |
| 7 | Ubs Group Ag | 2,260,325 | $18M | Added | Mar 2026 |
| 8 | Janney Montgomery Scott Llc | 2,016,464 | $16M | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 1,773,188 | $14M | Reduced | Mar 2026 |
| 10 | Morgan Stanley | 1,104,728 | $13M | Reduced | Dec 2025 |
| 11 | Adar1 Capital Management, Llc | 1,361,536 | $11M | New | Mar 2026 |
| 12 | Third Point Llc | 1,000,000 | $8M | Added | Mar 2026 |
| 13 | K2 Principal Fund, L.p. | 559,697 | $4M | Added | Mar 2026 |
| 14 | Northern Trust Corp | 529,284 | $4M | Added | Mar 2026 |
| 15 | Raymond James Financial Inc | 525,224 | $4M | Reduced | Mar 2026 |
| 16 | Vanguard Portfolio Management Llc | 510,551 | $4M | New | Mar 2026 |
| 17 | First Trust Advisors Lp | 422,038 | $3M | New | Mar 2026 |
| 18 | Jpmorgan Chase & Co | 382,801 | $3M | Reduced | Mar 2026 |
| 19 | Fmr Llc | 342,042 | $3M | Reduced | Mar 2026 |
| 20 | Bank Of America Corp /de/ | 285,728 | $2M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$951.2M
Enterprise Value
$802.6M
P/E (TTM)
-5.55x
Forward P/E
—
PEG Ratio
0.00x
P/B
8.32x
P/S
11.29x
P/FCF
-5.56x
EV/EBITDA
—
Shares Out
98.6M
Financials (TTM)
Revenue
$84.3M
Net Income
-$171.3M
EBITDA
-$178.1M
Free Cash Flow
-$171.2M
Op Cash Flow
-$170.9M
EPS Basic
$-1.74
EPS Diluted
$-1.74
EPS Forward
$-1.52
Gross Margin
75.8%
Op Margin
-212.9%
Net Margin
-203.3%
Balance Sheet
Total Assets
$327.7M
Total Liab.
$213.4M
Total Equity
$114.3M
Cash
$245.0M
LT Debt
$96.4M
Book Value/Sh
$1.16
Debt/Equity
0.85x
Current Ratio
7.28
Quick Ratio
7.06
Returns & Growth
ROE
-149.9%
ROA
-52.3%
ROIC
-62.0%
Rev Growth YoY
-5.5%
EPS Growth YoY
-2209.1%
Price Returns
2W
+14.2%
1M
+9.8%
3M
-2.3%
6M
-4.9%
12M
-37.1%
Technicals
52W High
$18.35
52W Low
$6.73
50d MA
$8.56
200d MA
$9.38
RSI (14)
57.30
ATR (14)
$0.57
Beta
0.93
Avg Volume
1.6M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$27.00
High
$30.00
Low
$25.00
Median
$26.00
Data updated apr 27, 2026 2:40am
· Source: financialmodelingprep.com